Артериальная гипертония как кардиотоксическая реакция на противоопухолевую терапию: что мы знаем о новом виде ятрогенной гипертонии
https://doi.org/10.18705/1607-419X-2018-24-4-384-395
Аннотация
Одним из ключевых регуляторов сосудистого тонуса является фактор роста эндотелия сосудов (VEGF), способный усиливать продукцию оксида азота, мощного вазодилататора, и уменьшать сосудистое сопротивление посредством генерации новых сосудов микроциркуляторного русла. Оба эти механизма способствуют снижению артериального давления. Появление нового класса противоопухолевой терапии — ингибиторов ангиогенеза — закономерно привело к росту такой нежелательной реакции, как артериальная гипертензия (АГ). Целью данной публикации является анализ причин развития АГ, подходов к своевременной диагностике АГ и корректной оценке сердечно-сосудистого риска — как при планировании, так и на фоне терапии ингибиторами ангиогенеза, особенностям коррекции АГ у пациентов, получающих таргетную терапию.
Об авторах
Ж. Д. Кобалава
Федеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов»
Россия
Россия
д.м.н., профессор, заведующая кафедрой пропедевтики внутренних болезней РУДН
ул. Миклухо-Маклая, д. 6, Москва, Россия, 117198
Е. К. Шаварова
Федеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов»
Россия
Россия
к.м.н., доцент кафедры внутренних болезней с курсом кардиологии и функциональной диагностики РУДН
ул. Миклухо-Маклая, д. 6, Москва, Россия, 117198
Список литературы
1. An MM, Zou Z, Shen H, Liu P, Chen ML, Cao YB et al. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol. 2010;66(8):813–21.
2. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2009;48(1):9. doi:10.1080/02841860802314720
3. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9(2):117–23.
4. Qi WX, Lin F, Sun YJ, Tang LN, He AN, Yao Y et al. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis. Cancer Chemother Pharmacol. 2013;71(2): 431–9.
5. Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2015;121(2):311–9.
6. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–30.
7. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358 (19):2039–2049.
8. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system. Circulation. 2011;124(15):1687–1691. doi:10.1161/CIRCULATIONAHA.110.992230
9. Hayman SR, Leung N, Grande JP, Garovic VD.VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep. 2012;14(4):285–94.
10. Zerbini G, Lorenzi M, Palini A. Tumor angiogenesis. N Engl J Med. 2008;359(7):763; author reply 764.
11. Carter JJ, Fretwell LV, Woolard J. Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats. FASEB J. 2017;31(3):1193–1203. doi:10.1096/fj.201600749R
12. Thijs AM, van Herpen CM, Sweep FC, Geurts-Moespot A, Smits P, van der Graaf WT et al. Role of endogenous vascular endothelial growth factor in endothelium-dependent vasodilation in humans. Hypertension. 2013;61(5):1060–1065. doi:10.1161/HYPERTENSIONAHA.111.00841
13. Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56(4):675–81. doi:10.1161/HYPERTENSIONAHA.109.149690
14. Verdonk K, Saleh L, Lankhorst S, Smilde JE, van Ingen MM, Garrelds IM et al. Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression. Hypertension. 2015;65(6):1316–1323. doi:10.1161/HYPERTENSIONAHA.115.05267
15. Lankhorst S, Kappers MH, van Esch JH, Smedts FM, Sleijfer S, Mathijssen RH et al. Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study. Hypertension. 2014;64(6):1282–1289. doi:10.1161/HYPERTENSIONAHA.114.04187
16. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition. Cell Signal. 2007:19(10);2003–12.
17. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008;19(5):927–34.
18. Steeghs N, Gelderblom H, Roodt JO, Christensen O, Rajagopalan P, Hovens M et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res. 2008;14(11):3470–6. doi:10.1158/1078-0432.CCR-07-5050
19. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR et al. Mechanisms of hypertension associated with BAY 43–9006. J Clin Oncol. 2006;24(9):1363–9.
20. Touyz RM, Lang NN, Herrmann J, van den Meiracker AH, Danser AHJ. Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition. Hypertension. 2017;70(2):220–226. doi:10.1161/HYPERTENSIONAHA.117.08856
21. Schneider BP, Li L, Shen F, Miller KD, Radovich M, O’Neill A et al. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer. 2014;111(6):1241. doi:10.1038/bjc.2014.430
22. Sibertin-Blanc C, Mancini J, Fabre A, Lagarde A, Del Grande J, Levy N et al. Vascular endothelial growth factor a c.*237C > T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer. Dig Liver Dis. 2015;47(4):331. doi:10.1016/j.dld.2014.12.013
23. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology. Eur Heart J. 2016;37(36):2768–2801. doi:10.1093/eurheartj/ehw211
24. Maitland LM, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ et al. Initial assessment, surveillance and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102 (9):596–604. doi:10.1093/jnci/djq091
25. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630.
26. Mir O, Ropert S, Alexandre J, Goldwasser F. Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol. 2009;20(5):967–970.
27. Rini BI, Cohen DP, Lu D, Chen I, Hariharan S, Gore ME et al. Hypertension (HTN) as a biomarker of efficacy in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib. J Natl Cancer Inst. 2011 May 4;103(9):763–73. doi:10.1093/jnci/djr128
28. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic metaanalysis. Cancer Chemother Pharmacol. 2010;66(2):357. doi:10.1007/s00280-009-1170-y
29. Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA et al. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist. 2013;18(3):273. doi:10.1634/theoncologist.2012-0339
30. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441–2447.
31. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370 (9604):2011–2019.
32. Maitland ML, Kasza KE, Karrison TG, Moshier K, Sit L, Black HR et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009;15(19):6250–6257. doi:10.1158/1078-0432.CCR-09-0058
33. Диагностика и лечение артериальной гипертензии. Российские рекомендации, четвертый пересмотр. Систем-ные гипертензии. 2010;3:5–26. [Diagnostics and management of arterial hypertension. Russian guidelines, 4th edition. Systemic Hypertension. 2010;3:5–26. In Russian].
34. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M et al. 2013 The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34 (28):2159–2219.
35. Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, Alexandre J et al. An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist. 2011;16(9):1325–1332. doi:10.1634/theoncologist.2010–0002
36. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med. 2008;358 (1):95–97.
37. Robinson ES, Matulonis UA, Ivy P, Berlin ST, Tyburski K, Penson RT et al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol. 2010;5(3):477–483. doi:10.2215/CJN.08111109
38. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49(2):186–93.
39. Lankhorst S, Baelde HJ, Clahsen-van Groningen MC, Smedts FM, Danser AH, van den Meiracker AH. Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib. Nephrol Dial Transplant. 2016;31(6):914–921. doi:10.1093/ndt/gfv410
40. Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010;1(7):628–38.
41. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K et al. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol. 2011;29(19):2635–44.
42. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011;29(19):2645–52. doi:10.1200/JCO.2010.33.4441
43. Zhang D, Ma QY, Hu HT, Zhang M. Beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting creb, nfkappab and ap-1. Cancer Biol Ther. 2010;10(1):19–29.
44. Liao X, Che X, Zhao W, Zhang D, Bi T, Wang G. The betaadrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor kappa-b signaling. Oncol Rep. 2010;24(6):1669–76.
45. Park PG, Merryman J, Orloff M, Schuller HM. Betaadrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: implications for individuals with preexisting chronic lung disease. Cancer Res. 1995;55(16):3504–8.
46. Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res. 2006;66(21):10357–64.
47. Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res. 2006;12(2):369–75.
48. Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R,Pouchy C et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011;2(10):797–809.
Рецензия
Для цитирования:
Кобалава Ж.Д., Шаварова Е.К. Артериальная гипертония как кардиотоксическая реакция на противоопухолевую терапию: что мы знаем о новом виде ятрогенной гипертонии. Артериальная гипертензия. 2018;24(4):384-395. https://doi.org/10.18705/1607-419X-2018-24-4-384-395
For citation:
Kobalava Zh.D., Shavarova E.K. Hypertension related to the antitumor treatment with angiogenesis inhibitors: an iatrogenic hypertension. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2018;24(4):384-395. (In Russ.) https://doi.org/10.18705/1607-419X-2018-24-4-384-395
Просмотров:
1916
Послать статью по эл. почте 